Paracetamol (acetaminophen) Price Trend and Forecast

Weekly Update
|
Historical Data Since 2015
|
Forecast for 2026
  • Commodity Pricing

paracetamol (acetaminophen) Price Trends by Country

cnChina
inIndia

Global paracetamol (acetaminophen) Spot Market Prices, Trend Analysis and Forecast

Price Watch™ provides price assessments for Paracetamol (Acetaminophen) across top trading regions:

Asia-Pacific

  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, India
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, India
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) FOB Hyderabad ICD, India
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) FOB Nhava Sheva Mumbai, India
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) Ex-Hebei, China
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) FOB Tianjin, China
  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) CIF Haiphong (China), Vietnam


North America

  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) CIF New York (India), USA


Europe

  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) CIF Valencia (India), Spain


South America

  • Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) CIF Santos, Brazil


Note:
In assessments structured as CIF [Importing Port] (Exporting Country), the country mentioned in brackets indicates the primary origin of supply (exporting country), while the named port refers to the destination port in the importing country. Other Incoterms (FOB, FD, EXW, etc.) should be interpreted in accordance with standard international trade definitions

Paracetamol (Acetaminophen) Price Trend Q4 2025

In Q4 2025, the global Paracetamol (Acetaminophen) market remained under pressure, as prices in both China and India continued to soften amid ongoing oversupply and cautious downstream demand. Across the two regions, quarter-on-quarter price declines of roughly 2-4% were observed largely driven by high inventory levels, aggressive export pricing and subdued buying from formulation manufacturers.

Production levels stayed stable and the lack of upward movement in upstream costs further supported the downward price adjustment. Although routine pharmaceutical demand and selective restocking offered some support overall market sentiment remained cautious. Looking ahead, the outlook stayed subdued with any potential recovery dependent on a rebound in demand, supply-side discipline or changes in global trade competitiveness.

China: Paracetamol (Acetaminophen) Export Prices FOB Tianjin, China, Pharma Grade (USP) (>99%) (Powder)

In Q4 2025, Paracetamol (Acetaminophen) prices in China moved in the range of USD 2,650-2,720 per metric ton posting a quarter-on-quarter decline of 1.90%. While the rate of price erosion slowed compared with the previous quarter, underlying market conditions remained weak, largely due to persistent global oversupply and subdued export demand. Downstream buyers continued to adopt a cautious procurement approach, drawing down existing stocks and covering only near-term requirements. Production levels at major manufacturing units stayed stable, limiting any scope for supply tightening. In the absence of clear demand recovery signals, the market ended the quarter with a bearish to range-bound outlook.

India: Paracetamol (Acetaminophen) Domestically Traded prices in Ex-Vadodara, India, Pharma Grade (IP) (>99%) (Powder)

In Q4 2025, Paracetamol (Acetaminophen) prices in India continued to weaken, settling into a lower consolidated range of USD 2730-2770 per metric ton and recording a 4.18% quarter-on-quarter decline. The extended correction was driven by comfortable domestic supply, elevated carryover stocks, and subdued export demand in the face of intense global API competition. Production rates remained largely unchanged, sustaining pressure on the supply side, while buyers largely limited purchases to immediate requirements. Although pharmaceutical consumption remained steady, it was not strong enough to absorb excess volumes, leaving market sentiment bearish with little near-term upside in sight.

Paracetamol (Acetaminophen) Price Trend Analysis: Q3 2025

In Q3 2025, the global Paracetamol (Acetaminophen) market maintained a bearish tone, with both China and India reflecting weakening sentiment driven by persistent oversupply and restrained downstream purchasing. Across the two regions, prices declined within a 2-8% quarter-on-quarter range, influenced by competitive export offers, subdued formulation demand, and steady production output. High inventory levels, limited export traction, and cautious purchasing behaviour continued to weigh on pricing, while the absence of upstream cost support reinforced the ongoing correction trend.

Despite the downtrend, baseline pharmaceutical consumption and selective restocking helped limit sharper price erosion. Looking ahead, market sentiment remains cautious, with any potential recovery contingent on demand improvement, supply adjustments, and shifts in global export competitiveness.

China: Paracetamol (Acetaminophen) Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q3 2025, Paracetamol (Acetaminophen) prices fell further into the USD 2,650-2,800 per metric ton range, registering a 7.53% quarter-on-quarter decline and marking the lowest level observed in the reviewed period. Persistent global oversupply conditions, continued competitive export environments, and hesitant buying behaviour contributed significantly to the correction.

Downstream procurement remained muted as formulation plants operated with strategic inventory control, while traders avoided speculative stocking due to uncertainty about stabilization. With no upstream cost support or notable shift in demand fundamentals, market direction remained firmly bearish, and expectations pointed toward only gradual recovery contingent on improved consumption or notable supply restructuring.

India: Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India)

According to Price-Watch AI, In Q3 2025, Paracetamol (Acetaminophen) Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara prices extended their downward trajectory, stabilizing within USD 2800-2900 per metric ton, reflecting a 3.16% quarterly decline. Abundant inventory levels and consistent domestic production continued to outweigh demand, resulting in a subdued trading environment. Export momentum remained limited due to competitive global API supply and price sensitivity among major importing regions.

Operating conditions at manufacturing sites stayed steady, further anchoring supply-side pressure. Market sentiment remained bearish, with most stakeholders expecting limited upside unless triggered by a supply disruption, regulatory shift, or notable improvement in downstream pharmaceutical consumption heading into the next quarter.

Global:

In Q2 2025, the Paracetamol (Acetaminophen) market across China and India continued trending downward with overall pricing declining in the 2-4% range as demand recovery remained limited and exports operated at moderate levels. Stable production rates, absence of supply disruptions, and steady cost inputs prevented any potential rebound while competitive offers particularly from China placed additional pressure on Indian negotiations.

Export activity also slowed, with buyers adopting a wait-and-watch approach amid expectations of further softening. Market sentiment overall remained cautious, and most procurement was aligned strictly with immediate consumption needs rather than speculative stocking, resulting in a persistently subdued trading environment through the quarter. 

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei 

In Q2 2025, prices eased further into the USD 2,850-3,000 per metric ton range, reflecting a 3.65% decline from Q1. Even though the rate of decline slowed, the trend remained downward as demand recovery remained limited, and exports continued at moderate levels. Production capacities remained steady, and the lack of supply disruptions prevented any rebound in values. Purchasing behaviour remained driven by immediate requirements, and most negotiations involved strong buyer-driven pricing strategies. With cost inputs stable and no new demand catalyst emerging, the market maintained a soft sentiment. 

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India)

In Q2 2025, the market reversed its prior upward tendency as prices softened into the INR 2900-3000 per metric ton bracket, marking a 2.47% decline. Weakening demand from downstream pharmaceutical units, coupled with steady-to-surplus supply volumes, contributed to a softer price environment. Market participants monitored regional pricing closely, especially in China, where competitive offers encouraged downward negotiation pressure in India.

Export orders also reduced in size and frequency as international buyers waited for improved price benchmarks. Purchasing sentiment turned cautious, with most buyers preferring short-term replenishment aligned with actual consumption.

Global:

In Q1 2025, the Paracetamol (Acetaminophen) market across China and India displayed mixed but generally stabilizing behaviour, with overall pricing movement falling within a 0.5-12% range quarter-on-quarter. China recorded a sharper correction as weak global demand, uninterrupted production and competitive export conditions placed pronounced downward pressure on values, prompting formulators in key importing regions to adopt short-term procurement strategies and avoid long contractual commitments.

India, meanwhile, experienced a comparatively firmer tone supported by improved order volumes tied to new production cycles, export commitments, and slightly stronger inquiry levels from Africa and the Middle East. Stable manufacturing operations in both markets ensured ample availability, preventing volatility despite differing momentum. While India leaned mildly bullish and China remained distinctly bearish, overall sentiment stayed cautious and range bound as market participants monitored demand signals and awaited clearer price stabilization cues.

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q1 2025, the market experienced another significant downward adjustment, with prices trending between USD 2,950-3,150 per metric ton and showing a 11.66% decline versus Q4. Weak global demand and highly competitive export dynamics resulted in deeper price pressure, especially in buyer-dominated regions.

Manufacturing operations in China continued uninterrupted, allowing ample supply to continue flowing into the marketplace. Formulators across Asia, Africa and Latin countries continued to procure cautiously, avoiding long-duration contracts and prioritizing short-term shipment cycles. The overall tone remained firmly bearish as participants monitored the market for a potential price floor.

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India).

In Q1 2025, pricing continued with a mildly bullish tone as the market traded between USD 3000-3150 per metric ton, recording a 0.93% quarterly increase. Higher order volumes from pharmaceutical manufacturers linked to new production cycles and export delivery commitments reinforced a firmer price base. The market also observed slightly improved global inquiries, especially from Africa and the Middle East.

Stable operating rates at manufacturing facilities-maintained supply continuity, preventing any sharp escalation. While sentiment shifted towards optimism, the market remained fundamentally range-bound, with buyers continuing strategic procurement rather than speculative stocking. 

Paracetamol (Acetaminophen) Price Trend Analysis: Q4 2024

Global:

In Q4 2024, the Paracetamol (Acetaminophen) market across China and India reflected a mixed but largely stable trend, with overall price movement falling within a 0.5%-5% quarterly range. In China, pricing softened amid steady production, sluggish export momentum, and buyer-driven negotiations as pharmaceutical manufacturers remained cautious and continued short-term procurement strategies due to expectations of further easing.

Meanwhile, India saw marginal upward movement supported by restocking ahead of year-end production cycles, seasonal consumption linked to analgesic and antipyretic formulations, and steady export participation. Controlled logistics and operating costs prevented significant volatility in both regions, while stable raw material inputs offered modest cost support. Despite contrasting regional behaviour, overall market sentiment remained cautious and competitive as participants monitored oversupply conditions, pricing discipline, and the balance between export activity and domestic demand heading into the next quarter.

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q4 2024, prices softened again, declining into the USD 3,300-3,500 per metric ton band and recording a 5.21% quarterly decrease. A combination of steady production rates and sluggish export momentum continued to weigh on pricing. Pharmaceutical manufacturers maintained careful purchasing strategies due to steady availability and expectations of further easing.

Logistics and operating costs remained controlled, offering no upward cost traction. Despite the falling trend, trade volumes remained consistent due to year-end contract fulfilments and export participation in tenders. However, the broader sentiment stayed cautious as the market continued adjusting to oversupply and price competition.

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India)

In Q4 2024, Paracetamol (Acetaminophen) prices showed marginal upward movement into the USD 3000-3100 per metric ton range, reflecting a 0.94% increase from Q3. The rise was supported by restocking demand ahead of the year-end production cycle and stable export activity from India. Seasonal consumption trends associated with analgesic and antipyretic medicines also contributed to stronger procurement behaviour.

While upstream raw material fluctuations were minor, they provided modest cost support, contributing to the gradual upward shift. Despite this recovery, pricing remained contained due to well-balanced domestic supply and cautious purchasing strategies from finished dosage manufacturers.

Global:

In Q3 2024, the Paracetamol (Acetaminophen) market across China and India moved into a stabilization phase, with overall pricing showing limited movement within a 0-0.5% range quarter-on-quarter. In China, prices recorded a modest uptick as buyers cautiously resumed scheduled procurement tied to production cycles, while manufacturers maintained controlled output to avoid renewed oversupply. Export interest gradually improved, particularly from generic drug formulators in Latin America and Africa, though purchasing remained highly price-sensitive.

In India, pricing remained stable with no major deviation from the previous quarter as inventory levels normalized and production operated in alignment with demand trends. Consistent domestic availability and steady import flows kept negotiation spreads narrow, while reduced volatility in both regions signaled a temporary market equilibrium driven by balanced supply, moderated demand, and disciplined purchasing strategies.

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q3 2024, the market entered a stabilization phase as prices steadied within the USD 3,600-3,750 per metric ton range, reflecting a modest 0.41% increase from the previous quarter. Buyers returned to the market cautiously after the earlier sharp decline, initiating scheduled procurement tied to production cycles rather than speculative stocking. Export inquiries showed gradual improvement, especially from generic drug manufacturers in Latin America and Africa, though purchasing remained price sensitive. Manufacturers maintained disciplined output to prevent further oversupply. As inventories normalized and demand steadied, the market saw reduced volatility and narrower negotiation spreads, creating a temporary equilibrium.

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India) 

In Q3 2024, pricing stabilized following two consecutive quarters of decline, moving within the USD 2950-3050 per metric ton bracket remained stable marking no change from the previous quarter. Inventory levels across primary distributors and formulation facilities reached a steady equilibrium, easing volatility and narrowing negotiation margins.

Domestic production continued uninterrupted, with utilization rates aligned to demand trends to prevent oversupply. The availability of imported material remained consistent, though it did not influence pricing significantly due to logistics, quality preferences, and lead-time considerations. With balanced supply and moderate procurement activity, the market saw minimal deviation in spot and contracted transaction levels. 

 

Global:

In Q2 2024, the Paracetamol (Acetaminophen) market across China and India underwent a pronounced correction, with overall pricing declining within a 4-14% range quarter-on-quarter as bearish sentiment strengthened. China saw steeper declines driven by aggressive export pricing, slowed global offtake, and inventory accumulation across trading networks, prompting buyers to delay large-volume commitments. India mirrored the downward momentum, though at a milder pace, as steady supply inflows, moderate production rates, and competitive regional offers continued to pressure domestic pricing.

Downstream pharmaceutical manufacturers in both markets shifted to cautious, demand-based purchasing strategies amid expectations of further easing, while stable raw material costs provided no upward push. With ample production capacity, controlled logistics, and limited export strength, transactional activity remained subdued, reinforcing expectations of continued softening in the short term.

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q2 2024, the pricing environment shifted sharply downward as values corrected to the USD 3,500-3,750 per metric ton range, marking a significant 13.38% decline from Q1. The drop was triggered by aggressive competitive pricing from multiple Chinese exporters and slow offtake from key global destinations. Inventory buildup across trading houses and bulk formulators deepened discounts, as many buyers refrained from committing to large-volume contracts. Weak downstream consumption and reduced purchasing momentum across Europe and South Asia contributed to subdued transactional activity. With ample production and no supply disruptions, sentiment turned decisively bearish, reinforcing expectations of continued downward pressure.

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India)

In Q2 2024, the downward trajectory continued as the market entered another corrective phase, with prices fluctuating within USD 2950-3050 per metric ton, reflecting a 4.22% quarterly decline. The market experienced steady supply inflows and moderate production rates, which supported price competition among producers and traders. Downstream pharmaceutical manufacturers continued purchasing on a need-basis to avoid overstocking amid expectations of further easing. Raw material costs, including para-aminophenol, remained largely stable, offering no cost-side support. Export momentum remained stable but not strong enough to shift market balances, while competitive offers from regional suppliers kept Indian prices under pressure.

Global:

In Q1 2024, the Paracetamol (Acetaminophen) Pharma Grade market across China and India showed contrasting movements, resulting in an overall price fluctuation within an 1-8% quarterly range. China experienced a mildly positive trend supported by steady export orders, improved inquiries from formulation sectors in Southeast Asia and the Middle East, and predictable supply chain conditions, allowing suppliers to maintain firmer offers despite only moderate demand.

In contrast, India saw a notable decline as high inventory carryover, subdued export momentum, and restrained procurement from formulation units weakened pricing sentiment. Both regions maintained stable production rates with no supply disruptions, but purchasing behaviour diverged-China benefitted from seasonal and export-linked activity, while India remained driven by short-term requirements and conservative stocking strategies.

Despite these differing regional dynamics, market sentiment overall remained cautious, with buyers closely monitoring cost conditions and demand recovery signals moving into the next quarter.

China: Pharma Grade (USP) (>99%) (Powder) FOB Tianjin, Pharma Grade (USP) (>99%) (Powder) Ex-Hebei

In Q1 2024, Paracetamol (Acetaminophen) Pharma Grade prices in China started the year on a slightly firmer note, moving within the USD 4,100-4,250 per metric ton range and registering a 1.61% increase compared to the prior quarter. The uptrend was primarily influenced by steady export orders and improved inquiries from formulation sectors in Southeast Asia and the Middle East.

Production rates remained consistent, but some manufacturers reported longer dispatch schedules due to heightened export booking cycles. Although demand was not aggressively strong, the balance between supply and movement allowed sellers to maintain relatively firm offers. Market sentiment leaned mildly positive, supported by predictable supply chains, stable feedstock availability, and a slight seasonal uplift in procurement.

India: Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara, Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana, Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD, Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva, Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India), Pharma Grade (USP) (>99%) (Powder) CIF New York (India) 

In Q1 2024, Paracetamol (Acetaminophen) Pharma Grade prices in India softened notably, reflecting a bearish start to the year amid restrained purchasing and sufficient stock availability across the value chain. Prices moved within the USD 3050-3200 per metric ton range, registering a 8.79% decline as inventory carried forward from late 2023 reduced urgency among buyers. Domestic producers maintained consistent operating rates, ensuring uninterrupted supply and reducing the likelihood of market tightness. Export inquiries remained lukewarm, particularly from South Asia and Africa, where buyers leaned toward shorter purchasing cycles. With no upstream cost push and sluggish consumption from formulation units, sentiment stayed weak and transactional behaviour remained conservative. 

 

Technical Specifications of Paracetamol (acetaminophen) Price Trends

Product Description:

Paracetamol (Acetaminophen) is a widely used analgesic and antipyretic medication essential for managing mild to moderate pain and reducing fever in various conditions such as headaches, muscle aches, toothaches, colds, flu, and post-surgical discomfort. It works primarily by inhibiting prostaglandin synthesis in the central nervous system and regulating body temperature through action on the hypothalamus. Unlike nonsteroidal Anti-inflammatory drugs paracetamol does not irritate the gastric lining and has no significant anti-inflammatory effects making it suitable for individuals who cannot tolerate aspirin or similar medications. It is commonly used across all age groups due to its favourable safety profile when taken within recommended dosage limits; however, excessive or prolonged use may lead to liver toxicity, particularly in individuals with liver disease or those consuming alcohol. Paracetamol (Acetaminophen) is available in multiple dosage forms, including tablets, capsules, syrups, suspensions, suppositories and injectable formulations, making it versatile and effective for diverse therapeutic applications.

Identifiers and Classification:

  • HS Code – 29222933
  • CAS No – 103-90-2
  • Molecular Formula – C₈H₉NO₂
  • Molecular Weight[g/mol] – 151.163 g/mol


Paracetamol (Acetaminophen) Synonyms:

  • Acetaminophen
  • Tylenol
  • Nonsteroidal Anti-inflammatory


Paracetamol (Acetaminophen) Grades Specific Price Assessment:

  • Pharma Grade (IP) (>99%) (Powder) Ex-Vadodara Price Trend
  • Pharma Grade (IP) (>99%) (Powder) Ex-Ludhiana Price Trend
  • Pharma Grade (EP) (>99%) (Powder) FOB Hyderabad ICD Price Trend
  • Pharma Grade (USP) (>99%) (Powder) FOB Nhava Sheva Price Trend
  • Pharma Grade (USP) (>99%) (Powder) CIF Valencia (India) Price Trend
  • Pharma Grade (USP) (>99%) (Powder) CIF New York (India) Price Trend
  • Pharma Grade (USP) (>99%) (Powder) Ex-Hebei Price Trend
  • Pharma Grade (USP) (>99%) (Powder) FOB Tianjin Price Trend
  • Pharma Grade (USP) (>99%) (Powder) CIF Haiphong (China) Price Trend
  • Pharma Grade (USP) (>99%) (Powder) CIF Santos (China) Price Trend


Paracetamol (Acetaminophen) Global Trade and Shipment Terms

  • Quotation Terms (Product & Country Specific): 25-30 MT
  • Packaging Type (Product & Country Specific): Bag (25KGs)


Incoterms Referenced in Paracetamol (Acetaminophen) Price Reporting

Shipping Term  Location  Definition 
Ex-Vadodara  Gujarat, India  Domestically Traded Paracetamol (Acetaminophen) price in India 
Ex-Ludhiana  Punjab, India  Domestically Traded Paracetamol (Acetaminophen) price in India 
FOB Hyderabad  Telangana, India  Paracetamol (Acetaminophen) Export price from India 
FOB Nhava Sheva  Mumbai, India  Paracetamol (Acetaminophen) Export price from India 
CIF Valencia (India)  Valencia, Spain  Paracetamol (Acetaminophen) Import price in Spain from India 
CIF New York (India)  New York, USA  Paracetamol (Acetaminophen) Import price in USA from India 
Ex-Hebei  Hebei, China  Domestically Traded Paracetamol (Acetaminophen) price in China 
FOB Tianjin  Tianjin, China  Paracetamol (Acetaminophen) Export price from India 
CIF Haiphong (China)  Haiphong, Vietnam  Paracetamol (Acetaminophen) Import price in Vietnam from China 
CIF Santos (China)  Santos, Brazil  Paracetamol (Acetaminophen) Import price in Brazil from China 

*Quotation Terms refers to the quantity range specified for the Paracetamol (Acetaminophen) being quoted or offered in a commercial transaction.

**Packaging Type refers to standard packaging size commonly used for Paracetamol (Acetaminophen) packing, ease of handling, transportation, and storage in industrial and commercial applications.

Key Paracetamol (Acetaminophen) Producing Regions and Countries

Region  Country 
Gujarat  India 
Punjab  India 
Telangana  India 
Mumbai  India 
Valencia  Spain 
New York  USA 
Hebei  China 
Tianjin  China 
Haiphong  Vietnam 
Santos  Brazil 

Paracetamol (acetaminophen) Industrial Applications

Historically, several events have caused significant fluctuations in Paracetamol (acetaminophen) prices

Impact ofUS Tariffs on Paracetamol (Acetaminophen) (2025) 

The US tariffs placed in 2025 on acetaminophen and other pharmaceutical APIs from China and India, totalling 20-25% of raw materials and intermediates, have dramatically increased production costs for enterprises who rely on these imports. This has resulted in API cost hikes of 12-20%, adding to increasing medicine pricing and reducing profit margins for generic producers who rely significantly on low-priced Asian supplies. Tariffs have also put pressure on supply chains by encouraging pharmaceutical companies to diversify their sourcing or invest in onshore or nearshoring production facilities in the United States and other lower-tariff jurisdictions, but such shifts are time-consuming and fraught with regulatory challenges, keeping supply constrained in the short term. These trade sanctions have caused price volatility and supply delays serving the US market.  

COVID-19 Pandemic Boosts Paracetamol Use (2020-2022)

During the global COVID-19 pandemic, paracetamol became a commonly recommended treatment for decreasing fever and treating pain in individuals infected with SARS-CoV-2. It was the first-line treatment due to its availability over-the-counter and relative safety. Due to extended or excessive use during the pandemic, this increase in use raised awareness of the possible risks of overdose and liver toxicity. 

Chinese PAP Export Disruptions (2018-2020)

From 2018 to 2020, China-supplying over 70% of global para-aminophenol (PAP), the critical raw material for paracetamol-implemented tightened export controls under its 2020 Export Control Law, which regulated dual-use chemicals like PAP for national security, non-proliferation and anti-terrorism purposes requiring prior licenses that caused shipment delays and reductions. Geopolitical factors, including US-China trade tensions, environmental factory shutdowns, and rising domestic paracetamol demand in China, exacerbated supply constraints, leading to up to 50% price surges and production halts for India. This triggered global paracetamol shortages, higher pharmaceutical costs and spurred diversification like India’s anti-dumping probes and backward integration with volatility persisting into 2025. 

S.-China Trade War (2018-2019)

In 2018, rising trade tensions between the United States and China started to impact pharmaceutical manufacturing and supply chains significantly. The U.S. implemented tariffs targeting Chinese chemical imports, including key pharmaceutical ingredients like para-aminophenol, essential for producing paracetamol. These tariffs increased costs and caused delays, posing challenges for manufacturers reliant on Chinese supplies. Meanwhile, the trade conflict encouraged companies to seek alternative suppliers and reconsider their supply strategies amid uncertain geopolitical conditions. This period marked the beginning of a broader shift in the global pharmaceutical industry to diversify supply chains and reduce dependency on any single country. 

Global Shortages from Manufacturing Inspections (2018)

In 2018, the FDA significantly intensified inspections of pharmaceutical manufacturing plants, especially those producing active pharmaceutical ingredients (APIs) overseas. Several facilities, particularly in India and China were found to have serious good manufacturing practice (GMP) violations such as contamination risks, inadequate quality controls and poor documentation. These discoveries led to import alerts and bans on shipments from these plants to the U.S. market, resulting in acute shortages of essential medicines like paracetamol.

Hospitals and healthcare providers faced challenges due to these shortages, as domestic production capacity was insufficient to compensate quickly. The events highlighted the pharmaceutical industry’s heavy reliance on foreign manufacturing and underscored the need for improved quality oversight and supply chain diversification to prevent similar disruptions in the future. The increased scrutiny also prompted manufacturers to enhance their compliance efforts and invest in supply chain resilience measures. 

Why Price Watch™?

Price Watch™ is your trusted resource for tracking global paracetamol (acetaminophen) price trends. Our platform delivers real-time data and expert analysis, offering deep insights into the key factors driving price fluctuations in the paracetamol (acetaminophen) market. By monitoring critical events such as geopolitical tensions, supply chain disruptions, and economic shifts, Price Watch™ keeps you fully informed of market dynamics.

In addition, Price Watch™ provides detailed forecasts and updates on production capacities, enabling you to anticipate market changes and make well-informed decisions. With Price Watch™, you gain a competitive edge in understanding all the elements that influence paracetamol (acetaminophen) prices worldwide. Stay ahead of the curve with Price Watch’s™ reliable, accurate, and timely paracetamol (acetaminophen) market data.

Track Price Watch's™ paracetamol (acetaminophen) price assessment on a weekly basis since 2015 onwards, along with short-term forecasts, and get access to the detailed report in a downloadable format.

Paracetamol (acetaminophen) Market Price Trend published by 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ reflect prevailing spot market conditions, derived from independent research, verified trade inputs, and proprietary market intelligence as of the publication date. Prices are published on the specified Incoterm and represent indicative base market levels, exclusive of applicable taxes, VAT, duties, tariffs, and other statutory charges. Actual transaction values may vary depending on volume, credit terms, contractual structure, and other negotiated conditions. Market prices are inherently subject to volatility, liquidity dynamics, regulatory changes, and evolving trade activity. The information provided is for reference and benchmarking purposes only and does not constitute an offer, recommendation, or guarantee of transactional outcomes. Users should exercise independent commercial judgment and assess their specific contractual, regulatory, tax, and application requirements before making business decisions. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ assumes no liability for decisions taken based on this information.

Paracetamol (Acetaminophen) Pricing Factors:
Paracetamol (Acetaminophen) pricing is shaped by a combination of global manufacturing capacity, supply-demand balances, pharmaceutical industry demand and raw material availability, especially in key producing regions such as China and India. Production output for Paracetamol (Acetaminophen) depends on access to chemical precursors, plant capacity utilization and regulatory practices governing pharmaceutical standards, all of which directly influence supply expectations. Market direction is heavily driven by demand from pharmaceutical sector with additional volatility created by inventory levels and export competitiveness among major suppliers.

Negotiating Paracetamol (Acetaminophen) Pricing:

Leverage market knowledge: Keep up to date with global Paracetamol (Acetaminophen) supply trends, demand cycles and pricing benchmarks to negotiate with confidence.

Pursue long-term contracts: Lock in pricing and ensure secure supply by entering agreements during low-price cycles, particularly in volatile periods.

Diversify sourcing: Compare quotes from multiple suppliers across regions to strengthen negotiation positions and hedge against local supply disruptions.

Foster supplier relationships: Develop trust and consistent communication to receive priority access and flexible terms in constrained supply scenarios.

Optimize logistics: Negotiate shipping terms and consider cost-effective delivery modes, as transport delays and freight charges heavily influence landed costs.

Paracetamol (Acetaminophen) Procurement Risks and Mitigation:

Price volatility: Paracetamol (Acetaminophen) prices are tied to CPO values and affected by global market sentiment and trade policy changes.
Mitigation: Implement hedging strategies (e.g., futures, fixed contracts) and monitor pricing trends for timely purchases.

Supply disruptions: Weather anomalies, plant shutdowns, and freight congestion can result in delivery delays or shortages.
Mitigation: Diversify suppliers geographically, maintain inventory buffers, and keep close tabs on climatic and operational updates.

Quality variability: Differences in moisture content and impurities foreign matter presence can affect suitability for downstream applications.
Mitigation: Enforce detailed product specifications, request COAs, and audit supplier production processes regularly.

Regulatory and currency risks: Trade policies and currency movements directly impact import costs.
Mitigation: Monitor regional trade policy developments and use currency hedging mechanisms when sourcing internationally.

Robust risk mitigation strategies and solid supplier alliances are essential for ensuring a reliable, cost-effective paracetamol (acetaminophen) supply.

Paracetamol (Acetaminophen) is one of the most widely used analgesic and antipyretic pharmaceutical ingredients, used to relieve pain and reduce fever. It is a core active ingredient in numerous over-the-counter (OTC) and prescription formulations, including tablets, syrups, suspensions, and combination drugs. Its price directly impacts medicine affordability, pharmaceutical manufacturing costs, public healthcare spending and procurement budgets for hospitals and government health programs. Because of its essential role in primary healthcare worldwide, Paracetamol pricing is a critical indicator for pharmaceutical supply chains. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ tracks these prices to help businesses and consumers understand and stay updated with the market trends.

Paracetamol (Acetaminophen) prices vary by region and grade. Prices are typically quoted per metric ton and change based on supply, demand, production methods, and energy costs. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ provides real-time price assessments across different global markets to help buyers and sellers make informed decisions.

Paracetamol prices are influenced by upstream raw material costs (such as Para-Aminophenol), production operating rates, inventory levels, export competitiveness and downstream pharmaceutical demand. Regulatory compliance costs, environmental norms, energy prices, freight rates, and global healthcare demand cycles also affect pricing. Demand surges during flu seasons, pandemics, or public health emergencies can tighten supply and lift prices, while oversupply and weak formulation demand can lead to price corrections.

The largest buyers of Paracetamol are pharmaceutical formulation companies producing tablets, syrups, capsules, and combination drugs. Significant demand also comes from OTC drug manufacturers, contract manufacturing organizations (CMOs), government healthcare procurement agencies, hospitals, and export-oriented pharmaceutical companies. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ analyses demand patterns across all these industries.

Paracetamol is synthesized through chemical processes using Para-Aminophenol as the key intermediate. It is manufactured by pharmaceutical API producers worldwide, with major production hubs in China and India, supported by integrated chemical supply chains, skilled manufacturing capacity, and large-scale export infrastructure.

China and India are the world’s largest exporters of Paracetamol, supplying bulk API to pharmaceutical companies across Asia, Europe, Africa, and the Americas. Export volumes depend on production capacity, regulatory approvals, cost competitiveness, currency movements, and global healthcare demand. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ tracks production levels, export flows and trade patterns to help businesses understand global supply chains and identify sourcing opportunities.

Under normal conditions, supply generally meets demand. However, shortages can occur due to plant shutdowns, regulatory inspections, raw material disruptions, environmental compliance issues, or sudden demand spikes during health emergencies. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ monitors these supply-demand imbalances to alert the market about potential shortages or surpluses.

Paracetamol is available in multiple pharmacopeial grades, including IP, BP, USP and EP, each with specific purity and compliance requirements. Higher-purity grades and those meeting stringent regulatory standards command premium prices. Pricing also varies based on particle size, formulation suitability, manufacturing consistency, certifications, and audit readiness. Export-oriented and regulated-market grades typically trade at higher prices than domestic or non-pharma specifications. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ provides separate price assessments for each grade to ensure market transparency.

When demand spikes often during flu seasons, pandemics or public health emergencies prices typically rise as inventories tighten and lead times extend. Manufacturers may prioritize long-term or government contracts, while spot buyers may face higher prices or limited availability. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ captures these market dynamics in real-time.

Energy costs significantly influence Paracetamol production, as chemical synthesis, drying, and quality control processes are energy intensive. Rising electricity, fuel, or steam costs increase manufacturing expenses, which are often passed on to buyers. Transportation and export logistics further amplify energy-related cost impacts. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ analyses in its price assessments & market reports.

Regional price differences arise from variations in production capacity, regulatory compliance costs, raw material availability, labor and energy costs, freight rates, currency movements, and local demand conditions. Regions with integrated chemical supply chains and strong export infrastructure generally offer more competitive pricing, while regulated markets often see higher prices. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ tracks prices across all major regions to highlight these differences.

The Paracetamol (Acetaminophen) market outlook depends on raw material trends, global healthcare demand, production operating rates, regulatory developments, freight costs, and macroeconomic conditions. Seasonal demand patterns and potential supply side disruptions also play a role. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ regularly publishes detailed forecasts that project price movements for the next 12 months based on comprehensive analysis of supply additions, demand growth in key industries, seasonal patterns, and macroeconomic indicators. Our forecasts help businesses anticipate market conditions and plan accordingly.

Absolutely. Reliable forecasts help pharmaceutical companies and traders optimize procurement timing, negotiate contracts more effectively, manage inventory risks, and improve budgeting accuracy. If 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ forecasts predict a price increase in three months, you might choose to stock up now or lock in long-term contracts at current rates, potentially saving thousands of dollars.

Global events such as pandemics, regulatory crackdowns, environmental inspections, raw material shortages, logistics disruptions, trade restrictions or geopolitical tensions can significantly impact Paracetamol supply and pricing. Sudden surges in healthcare demand or export limitations can trigger sharp price movements. 𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ provides timely alerts when such events affect the market.

𝐏𝐫𝐢𝐜𝐞 𝐖𝐚𝐭𝐜𝐡™ collects data from manufacturers, distributors, and buyers worldwide to publish regular price assessments, market reports, and forecasts. Our transparent methodology and comprehensive coverage make us a trusted source for understanding fair pricing and market trends in the Paracetamol (Acetaminophen) industry.